News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase III
Amgen (AMGN)'s Repatha Met Co-Primary Endpoints in Phase III GAUSS-3 Study 2/5/2016
Amgen (AMGN)'s Blincyto Successful in Phase III Leukemia Trial 2/5/2016
Can-Fite BioPharma (CFBI) To Present At BIO CEO & Investor Conference In New York City On February 8, 2016 2/5/2016
Immunomedics (IMMU)'s Breast Cancer Drug Wins Breakthrough Tag from the FDA 2/5/2016
Dipexium Pharmaceuticals (DPRX) Reaches 75% Enrollment Milestone In Pivotal Phase 3 Clinical Trials 2/4/2016
Ascendis Pharma A/S To Present At The Leerink Partners Global Healthcare Conference 2/4/2016
ContraVir To Present At Two Upcoming Investor Conferences 2/4/2016
ERYtech Pharma To Present At Upcoming Investor Conferences 2/4/2016
OSE Pharma Announces U.S. Initiation Of Atalante 1, The Company’s Global, Pivotal Phase III Trial For Tedopi Immunotherapy In Non-Small Cell Lung Cancer 2/4/2016
Invetech And Celyad Announce Collaboration To Realize The Commercial cGMP Production Of C-Cure 2/3/2016
Gilead (GILD) Announces Fourth Quarter And Full Year 2015 Financial Results 2/3/2016
Carbylan Therapeutics Ostearthrtis Drug Gets Half the Job Done in Late-Stage Study 2/2/2016
Versartis, Inc. (VSAR) Reports Confirmatory Top-Line Two-Year Data From Ongoing Extension Study Of Somavaratan In GHD Children 2/2/2016
Array BioPharma (ARRY) Reports Financial Results For The Second Quarter Of Fiscal 2016 2/2/2016
Tenax Therapeutics (TENX) Provides Update Of Phase 3 LEVO-CTS Trial For LCOS 2/2/2016
GlycoMimetics, Inc. (GLYC) To Present At 18th Annual BIO CEO & Investor Conference 2/2/2016
AEterna Zentaris (AEZS) To Participate In 18th Annual BIO CEO & Investor Conference Seeking Partnering Opportunities 2/2/2016
Provectus Biopharmaceuticals Inc. To Present At 18th Annual BIO CEO & Investor Conference 2/2/2016
Pfizer (PFE) Reports Fourth-Quarter And Full-Year 2015 Results 2/2/2016
Comeback Kid Exelixis (EXEL)' Touts Positive Phase III Cancer Data 2/1/2016
Tenax Therapeutics (TENX) Provides Update Of Phase III LEVO-CTS Trial For LCOS 2/1/2016
Steba Biotech Announces Positive Top-Line Results From Its Latin American Phase 3 Clinical Trial Of TOOKAD In Patients With Localized Prostate Cancer And Obtains First Marketing Authorization In Mexico 2/1/2016
Jazz Pharmaceuticals (JAZZ) Release: Results From Phase 3 Trial Of Defibrotide For The Treatment Of Severe Veno-Occlusive Disease And Multi-Organ Failure Published Online In BLOOD 2/1/2016
Recro Pharma (REPH) Initiates Second Pivotal Phase III Clinical Trial Of IV Meloxicam For Acute Postoperative Pain 2/1/2016
RegeneRx Biopharmaceuticals, Inc. (RGRX) Meeting With Institutional Investors And Analysts At BIO CEO Conference 2/1/2016
CytRx Corporation (CYTR) To Present At The 18th Annual BIO CEO & Investor Conference 2/1/2016
CEL-SCI (CVM) Reports Monthly Patient Enrollment In January For Its Phase III Head And Neck Cancer Trial 2/1/2016
Aimmune (AIMT) To Present At The 18th Annual BIO CEO & Investor Conference 2/1/2016
Inotek Pharmaceuticals Corporation (ITEK) Announces Participation In Ophthalmology Panel At 18th Annual BIO CEO & Investor Conference On February 8th 2/1/2016
Alnylam (ALNY) Completes Enrollment In APOLLO Phase III Study With Patisiran, An Investigational Rnai Therapeutic For Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis) 2/1/2016
Tenax Therapeutics (TENX) Provides Update Of Phase 3 LEVO-CTS Trial For LCOS 2/1/2016
Allergan (AGN)'s Rapastinel Snags Breakthrough Tag from the FDA for Depression 1/29/2016
RegeneRx Biopharmaceuticals, Inc. (RGRX) Announces Completion of Patient Enrollment In Phase 2b/3 U.S. Dry Eye Trial 1/29/2016
AbbVie (ABBV) Reports Full-Year 2015 and Fourth-Quarter Financial Results 1/29/2016
Bristol-Myers Squibb (BMY) And AbbVie (ABBV) Receive Positive CHMP Opinion Forinvestigational Antibody, Empliciti (Elotuzumab), For The Treatment Of Multiple Myeloma In Patients Who Have Received At Least One Prior Therapy 1/29/2016
Spectrum Pharma (SPPI) Begins Enrolling Patients In Registrational Trial Of SPI-2012, A Novel, Long Acting G-CSF In Patients With Breast Cancer 1/29/2016
Innovative Med Concepts Announces Receipt Of FDA Fast Track Designation For IMC-1, A Novel Treatment For Fibromyalgia 1/29/2016
AbbVie (ABBV)'s Venetoclax Wins 3rd Breakthrough Tag from the FDA 1/28/2016
AbbVie (ABBV) Initiates Enrollment In Phase 3 Clinical Program For Elagolix In Patients With Uterine Fibroids 1/28/2016
Rigel (RIGL) Completes Enrollment Of First Phase 3 Study Of Fostamatinib In ITP (FIT) 1/28/2016
Vertex (VRTX) Reports Full-Year And Fourth Quarter 2015 Financial Results 1/28/2016
Merck & Co. (MRK) Completes Enrollment In Pivotal Phase 3 "EPOCH" Trial Investigating The Efficacy And Safety Of Verubecestat In Patients With Mild-To-Moderate Alzheimer’s Disease 1/28/2016
Bristol-Myers Squibb (BMY) Reports Fourth Quarter And Full Year 2015 Financial Results 1/28/2016
Bristol-Myers Squibb (BMY) Release: CheckMate -141, A Pivotal Phase 3 Opdivo (Nivolumab) Head And Neck Cancer Trial, Stopped Early 1/28/2016
Celgene (CELG) Reports Fourth Quarter And Full Year 2015 Operating And Financial Results 1/28/2016
Catalent Biologics And Cerenis Therapeutics, Inc. Announce Phase III Trial Of CER-001 In Europe And North America Leveraging GPEx Cell Line Technology 1/28/2016
ImmunoCellular Therapeutics, Ltd (IMUC) Enters Into A Sponsored Research Agreement With The University of Maryland, Baltimore To Pursue Multiple Enhancements Of Its Cancer Immunotherapy Platforms 1/27/2016
Boehringer Ingelheim's Gilotrif (afatinib) Demonstrated Superiority To Iressa (gefitinib) In Reducing The Risk Of Disease Progression And Treatment Failure In First-Line Treatment Of Patients With EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer 1/27/2016
Recro Pharma (REPH) Initiates Pivotal Phase III Clinical Trial Of IV Meloxicam For Acute Postoperative Pain 1/27/2016
Biogen (BIIB) 2015 Revenues Increase 11% To $10.8 Billion 1/27/2016
Ophthotech Corporation (OPHT) Announces First Patient Dosed In Zimura Phase 2/3 Study To Evaluate Treatment In Patients With Geographic Atrophy, An Advanced Form Of Dry Age-Related Macular Degeneration 1/27/2016
Ipsen (IPN.PA) Announces Publication In Pediatrics Of The Results Of The Phase III Randomized Study Showing The Efficacy And Safety Of Dysport(Abobotulinumtoxina) In Children With Dynamic Equinus Foot Deformity Due To Cerebral Palsy 1/27/2016
Boehringer Ingelheim Release: Idiopathic Pulmonary Fibrosis (IPF): OFEV (Nintedanib) Is Recommended For Use Within The NHS By The National Institute For Health And Care Excellence (NICE) 1/27/2016
Prima Biomed (PRR.AX) Initiates Phase I Melanoma Study In Australia 1/27/2016
FDA Accepts Amgen (AMGN)'s Biosimilar Biologics License Application For ABP 501 1/26/2016
US FDA Accepts Green Cross' Biologics License Application For IVIG-SN 1/26/2016
Soligenix (SNGX) Provides 2016 Business Outlook 1/26/2016
Zafgen (ZFGN) Falls as Hedge Fund Shorts Stock, Claims Obesity Drug Will Not Gain FDA Approval 1/25/2016
Cytori Therapeutics, Inc. (CYTX) Update On Its U.S. Phase III Scleroderma Trial 1/25/2016
Celgene (CELG) Release: Data Presented At ASCO GI Highlight The Feasibility Of Second-Line Treatment In Patients With Metastatic Pancreatic Cancer Who Have Received First-Line Abraxane Plus Gemcitabine 1/25/2016
Steba Biotech Completes Its European Phase 3 Clinical Trial Of TOOKAD In Patients With Low-Risk Prostate Cancer And Submits Marketing Authorization Application To The European Medicines Agency 1/25/2016
Broad Institute Genomic Services Partners With Takeda (TKPYY) To Offer Genomic Insight Into The Recently Approved Therapeutic NINLARO (ixazomib) 1/25/2016
Shire (SHPG) Resubmits New Drug Application For Lifitegrast To U.S. FDA 1/25/2016
Valeant (VRX) Announces FDA Acceptance Of BLA Submission For Brodalumab In Moderate-To-Severe Plaque Psoriasis 1/25/2016
Can-Fite BioPharma (CFBI) CEO Dr. Pnina Fishman To Chair Scientific Session At The 2016 Purinergic Signaling And Cancer Immunotherapy Conference In Vancouver On January 26, 2016 1/25/2016
Amgen (AMGN)'s Vectibix + BSC Meets Primary Endpoint in Phase III Study 1/25/2016
Stock Craters as Alkermes (ALKS)' Depression Drug Fails in Two Late-Stage Trials 1/22/2016
Genentech (RHHBY) Sponsored Study Reveals Hidden Stigma of Lung Cancer 1/22/2016
NephroGenex (NRX) Announces Independent DSMB Recommendation To Continue Phase 3 Study Of Oral Pyridorin In Diabetic Nephropathy Without Modification 1/22/2016
AbbVie (ABBV) CEO Argues Value of Company’s Pipeline, Piques Analysts Interest 1/21/2016
Investors Rejoice as Zafgen (ZFGN)'s Obesity Drug Performs Well in Phase III Study, New Data May Lift Clinical Hold 1/21/2016
EyeGate Pharma Enrolls First Patient In Confirmatory Phase 3 Clinical Trial EGP-437-006 For Non-infectious Anterior Uveitis 1/21/2016
Alkermes (ALKS) Announces Topline Results Of FORWARD-3 And FORWARD-4, Two Phase 3 Studies Of ALKS 5461 In Major Depressive Disorder 1/21/2016
Allergan (AGN) Release: VIBERZI (eluxadoline) Phase III Trial Results Published In The New England Journal of Medicine 1/21/2016
AcelRx (ACRX) Announces Presentation Of Phase 3 Sufentanil Sublingual 30 Mcg Tablet (ARX-04) Data At The European Congress Of Ambulatory Surgery 1/21/2016
Philogen S.p.A. Announces Commencement Of Phase III Pivotal Trial In Melanoma 1/21/2016
Merrimack (MACK) Release: Updated Data Shows ONIVYDE (irinotecan liposome injection) Combination Regimen Increased One Year Survival By 63% In Patients With Metastatic Pancreatic Cancer 1/20/2016
Delcath Systems (DCTH) Announces Initiation Of Phase 3 Trial Of Melphalan/Hds System For Treatment Of Hepatic Dominant Ocular Melanoma 1/20/2016
Bayer (BAY) To Highlight Latest Stivarga (regorafenib) Tablets Research At ASCO GI 2016 1/20/2016
AbbVie (ABBV) and Roche (RHHBY)'s Venetoclax Snags Breakthrough Tag from the FDA for Blood Cancer 1/20/2016
Up or Down, Three Biotechs that Will Face Major Decisions Soon 1/19/2016
Eleven Biotherapeutics (EBIO) Stock Plunges on Yet Another Failed Clinical Trial 1/19/2016
Biogen (BIIB)'s Promising Pipeline Underscores CEO’s High-Risk Strategy 1/19/2016
Eli Lilly (LLY) And Incyte (INCY) Announce Submission Of New Drug Application To FDA For Oral Once-Daily Baricitinib For Treatment Of Moderate-To-Severe Rheumatoid Arthritis 1/19/2016
Delcath Systems (DCTH) Announces Special Protocol Assessment Agreement With FDA For New Phase 3 Trial In Hepatic Dominant Ocular Melanoma 1/19/2016
AEterna Zentaris (AEZS) Concludes Successful Meeting Of Clinical Investigators For Confirmatory Phase III Trial Of Macrilen 1/19/2016
Merck & Co. (MRK) Release: Data For KEYTRUDA (pembrolizumab) In A Range Of Gastrointestinal Cancers To Be Presented At 2016 Gastrointestinal Cancers Symposium 1/19/2016
Trevena, Inc. (TRVN) Announces Initiation Of Oliceridine Phase 3 Clinical Program With Multi-Procedure Safety And Tolerability Study 1/19/2016
Omeros Corporation (OMER) Release: Disclosure Of Omidria Post-Launch Study Findings To Occur At Hawaiian Eye And Retina Conference 1/18/2016
Key Points Amgen (AMGN) CEO Bob Bradway Made at J.P. Morgan 1/15/2016
Geron Corporation (GERN) Announces Initiation Of Janssen Phase II/III Clinical Trial Of Imetelstat In Myelodysplastic Syndromes 1/14/2016
Brilacidin Lyophilized As Cellceutix (CTIX) Prepares To Bring First New Class Of Antibiotic To Phase 3 Trials In More Than 20 Years 1/14/2016
Glioblastoma Treatment Market Will Expand to $3.3 Billion by 2024, GlobalData Report Says 1/14/2016
Esperion (ESPR) Announces Initiation Of Phase 3 Clinical Program With Long-Term Safety And Tolerability Study 1/13/2016
Segal Institute For Clinical Research Proudly Participates In Phase III Efficacy Trial Of Long-Acting Treatment Opioid Dependence 1/13/2016
Ionis (IONS) Completes Target Enrollment For Nusinersen Phase 3 Study, CHERISH, In Children With Spinal Muscular Atrophy 1/12/2016
CrystalGenomics Partners With TR-Pharm For Acelex Commercialization In Turkey And MENA 1/12/2016
Kowa Research Institute, Inc. Release: Landmark Trial Entitled "PROMINENT" To Explore The Prevention Of Heart Disease In Diabetic Patients With High Triglycerides And Low HDL-C 1/12/2016
Inotek Pharmaceuticals Corporation (ITEK) Appoints Carsten Boess To Board Of Directors 1/12/2016
Cardiorentis Bags $60 Million and Adds Two Key Senior Execs to the Roster 1/11/2016
Merrimack (MACK) To Present Updated Overall Survival Analysis Of Phase 3 NAPOLI-1 Study Of ONIVYDE (irinotecan liposome injection) At The ASCO 2016 Gastrointestinal Cancers Symposium 1/11/2016
Sorrento Announces Positive Data From Phase 3 Studies Of Biosimilar Antibodies, STI-001 And STI-002 1/11/2016
AbbVie (ABBV) Initiates Enrollment Of Six Global Phase 3 Clinical Studies For Once-Daily, Pan-Genotypic Hepatitis C Regimen 1/11/2016
SELLAS Life Sciences Announces Orphan Drug Designation For WT1 Cancer Vaccine In Patients With Acute Myeloid Leukemia (AML) 1/11/2016
CytRx Corporation (CYTR) Appoints Olivia Ware As Chief Commercial Officer 1/11/2016
Aquinox (AQXP) Announces Update On Development Program For AQX-1125 Following Meeting With FDA 1/11/2016
Coherus And Baxalta (BXLT) Announce CHS-0214 (Investigational Etanercept Biosimilar) Met Primary Efficacy Endpoint In Phase III Rheumatoid Arthritis Clinical Study (Rapsody) 1/11/2016
PTC Therapeutics (PTCT) Outlines Business Priorities For The Development And Commercialization Of Translarna And Progress Of The Company Pipeline 1/11/2016
Cytokinetics (CYTK) Outlines Vision 2020 Strategic Initiative To Advance Portfolio Of Muscle Biology Drug Candidates 1/11/2016
Cytokinetics (CYTK) Presents Analyses Demonstrating Predictive Value Of Slow Vital Capacity For Clinical Outcomes In ALS 1/11/2016
Cyclacel Pharmaceuticals, Inc. (CYCC) Reviews 2015 Achievements And Announces Key Business Objectives For 2016 1/11/2016
Aimmune (AIMT) Enrolls First Patient In Phase III PALISADE Trial Of AR101 For The Treatment Of Peanut Allergy 1/11/2016
TiGenix Announces Acceptance Of Cx601 Abstract For Presentation At ECCO 2016 Congress 1/11/2016
CTI BioPharma Announces Positive Progress Of Lead Clinical Programs And General Outlook For Transformational 2016 1/11/2016
Ironwood (IRWD) Details Strategy To Build Top-Performing Commercial Biotechnology Company 1/11/2016
Alnylam (ALNY) Outlines 2016 Goals For RNAi Therapeutics Pipeline 1/11/2016
Celator Pharmaceuticals, Inc. Announces Participation In Cardiff University Clinical Trial In Adults With Acute Myeloid Leukemia Or High-Risk Myelodysplastic Syndrome (AML19) 1/11/2016
Infinity Pharmaceuticals Inc. (INFI) Provides Key 2016 Goals And Financial Guidance 1/11/2016
AcelRx (ACRX) Announces Anticipated 2016 Milestones 1/11/2016
Tokai Pharmaceuticals (TKAI) Announces Presentation Of New Data Highlighting Unique Galeterone Mechanism At ASCO Genitourinary Cancers Symposium 1/11/2016
Ocular Therapeutix (OCUL) Strengthens Executive Management Team With The Appointment Of Highly Regarded Ophthalmologist Jonathan H. Talamo, M.D., As Chief Medical Officer 1/11/2016
Incyte (INCY) Presents Significant Progress In Its Development Portfolio 1/11/2016
Celgene (CELG) Announces 2016 Financial Outlook And Preliminary 2015 Results 1/11/2016
Enanta Pharmaceuticals, Inc. Announces That AbbVie (ABBV) Has Initiated Enrollment Of Six Global Phase 3 Clinical Studies Of Its Once-Daily, Pan-Genotypic Hepatitis C Treatment 1/11/2016
Can-Fite BioPharma (CFBI) Announces 2016 Clinical Milestones For Its Pipeline Of Drugs In Six Indications 1/11/2016
NanoString (NSTG) Touts Collaborative Work in Immuno-Oncology at J.P. Morgan Conference 1/11/2016
AcelRx (ACRX) Completes Protocol Review With FDA And Plans To Initiate Phase 3 Open-Label Study (IAP312) For Zalviso In 1Q 2016 1/8/2016
PTC Therapeutics (PTCT) Completes Rolling NDA Submission To FDA And Submits Phase 3 ACT DMD Clinical Trial Results To European Medicines Agency for Translarna (ataluren) For Treatment Of Nonsense Mutation Duchenne Muscular Dystrophy 1/8/2016
Regeneron (REGN) And Sanofi (SNY) Announce Sarilumab Biologics License Application Accepted For Review By US FDA 1/8/2016
AbbVie (ABBV) Announces The Launch Of Robust Phase 3 Clinical Trial Program Evaluating ABT-494, An Investigational Selective JAK1 Inhibitor, For The Treatment Of Rheumatoid Arthritis 1/8/2016
Revance Therapeutics, Inc. (RVNC) Specifies 2016 Clinical Program Milestones 1/8/2016
NW Bio (NWBO) Issues Statement On Adverse Market Conditions And NW Bio Stock Decline 1/8/2016
Can-Fite BioPharma (CFBI) To Present At Biotech Showcase In San Francisco On January 13, 2016 1/8/2016
ViiV Healthcare To Progress Collaboration With Janssen To Develop The First Long-Acting, Two Drug Injectable Regimen For Treatment Of HIV-1 Infection 1/7/2016
U.S. FDA Grants Priority Review To AbbVie (ABBV) For Supplemental New Drug Application For VIEKIRA PAK (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) Without Ribavirin In Genotype 1b Chronic Hepatitis C Virus Patients With Compensated Cirrhosis 1/7/2016
Cynapsus Therapeutics (CYNA) And Michael J. Fox Foundation Collaborate On Pilot Use Of Wearable Device And Data Science Approaches In Phase 3 Parkinson's Clinical Study 1/7/2016
Genticel To Evaluate Roche Molecular Systems (RHHBF.PK)’ cobas HPV Test In Preparation For PhIII Program Of GTL001 1/7/2016
Nektar Therapeutics (NKTR)' President And CEO, Howard W. Robin, To Present At The 34th Annual J.P. Morgan Healthcare Conference In San Francisco, CA 1/7/2016
Galera Announces Fast Track Designation Of GC4419 For Prevention Of Oral Mucositis 1/7/2016
Mast Therapeutics (MSTX) Provides Business Update 1/7/2016
Tokai Pharmaceuticals (TKAI) Announces Update On ARMOR3-SV And Expanded Galeterone Clinical Development Program 1/7/2016
Dynavax (DVAX) Surges as Hep B Vaccine Meets Goals in Phase III Study 1/7/2016
Exelixis (EXEL)'s Cabozantinib Shines in Late Stage Study for Patients with Advanced RCC 1/6/2016
SillaJen Announces First Patient Randomized In Multinational Phase 3 Trial For Pexa-Vec In Advanced Liver Cancer 1/6/2016
Vtesse, Inc. Announces FDA's Granting Of Breakthrough Therapy Designation For VTS-270 In Niemann-Pick Type C1 Disease 1/6/2016
CorMedix (CRMD) To Present At Biotech Showcase 2016 1/6/2016
Cytori Therapeutics, Inc. (CYTX) To Provide Corporate Update At 2016 Biotech Showcase 1/6/2016
OSE Pharma Announces Initiation Of Its Pivotal Phase 3 trial Of Tedopi In Non-Small Cell Lung Cancer 1/6/2016
Aimmune (AIMT) To Present At The 34th Annual J.P. Morgan Healthcare Conference 1/6/2016
TRANSGENE (ENX:TNG) Announces First Patient Randomized In Multinational Phase 3 Trial For Pexa-Vec Oncolytic Immunotherapy In Advanced Liver Cancer 1/6/2016
Exelixis (EXEL) Announces Positive Results From Subgroup Analyses Of The METEOR Phase 3 Pivotal Trial Of Cabozantinib In Advanced Renal Cell Carcinoma To Be Presented At ASCO 2016 Genitourinary Cancerssymposium 1/5/2016
Investors Await Four Key FDA Decisions in the First Quarter of 2016 1/5/2016
Ardelyx (ARDX) Reports Positive Clinical Results Of RDX022 For The Treatment Of Hyperkalemia 1/5/2016
Acacia Pharma Announces Positive Results From Second Pivotal Phase 3 Study Of BAREMSIS (APD421) In Prevention Of Post-Operative Nausea & Vomiting 1/5/2016
Can-Fite BioPharma (CFBI) Submits Phase III Protocol To IRB For CF101 In The Treatment Of Rheumatoid Arthritis 1/5/2016
CoLucid Pharma (CLCD) And IMS Health Publish White Paper To Address Migraine Market Misperceptions 1/5/2016
ContraVir To Present At Biotech Showcase 2016 1/5/2016
Armetheon To Participate In Two Events During Week Of J.P. Morgan Healthcare Conference 1/5/2016
Gilead (GILD) Announces Top-Line Results From Two Phase III Studies Evaluating Tenofovir Alafenamide (TAF) For Patients With Chronic Hepatitis B Infection 1/5/2016
CEL-SCI (CVM) Reports Record Year For Patient Enrollment With 75% Increase In Its Global Phase III Head And Neck Cancer Trial 1/5/2016
Akebia (AKBA) Initiates Phase 3 PRO2TECT Program 1/5/2016
Ionis (IONS) To Present At The 34th Annual J.P. Morgan Healthcare Conference 1/4/2016
Halozyme (HALO) Enters Into Agreement For $150 Million Non-Dilutive Royalty-Backed Debt Financing 1/4/2016
Acerus (TRLPF) Announces NATESTO Publication In Prominent Andrology Journal 1/4/2016
Braeburn Pharma And Camurus Enroll First Patient In A Phase 3 Efficacy Trial Of Long-Acting Treatment For Opioid Dependence 12/30/2015
Anika Therapeutics (ANIK) Announces First Patient Enrolled in FastTRACK Phase III HYALOFAST Study 12/30/2015
Chimerix (CMRX) Shares Plunge After Brincidofovir Fails in Phase III Trial 12/29/2015
Faron Pharmaceuticals Ltd. Release: First Patient Recruited In Pan-European Phase III INTEREST Study For Treatment Of Acute Respiratory Distress Syndrome 12/29/2015
Adamas Pharmaceuticals (ADMS)' Lead Drug ADS-5102 Meets Phase III Goals; Stock Surges 12/28/2015
RestorGenex (RESX) and Diffusion Pharma Merge to Form Wholly-Owned Oncology Subsidiary 12/28/2015
Novartis Pharmaceuticals Corporation (NVS) Announces Publication Of Two Landmark Studies In The New England Journal of Medicine Demonstrating Efficacy Of Cosentyx In Patients With Ankylosing Spondylitis 12/28/2015
pSivida (PSDV) Skyrockets on Phase III Medidur Trial Results 12/23/2015
Pfizer (PFE)'s Pristiq Fails to Beat Placebo in Phase III MDD Study 12/23/2015
Kamada Ltd. (KMDA)'s Rabies Drug KamRab Meets Phase II/III Primary Endpoint 12/23/2015
Intra-Cellular Therapies Reports Initiation Of Patient Enrollment For ITI-007 Phase 3 Clinical Trials In Bipolar Depression 12/23/2015
Merck KGaA (MKGAF.PK), Pfizer (PFE) Accelerate Immuno-Oncology Drug Avelumab into Phase III Ovarian and Bladder Cancer Trials 12/22/2015
BeyondSpring Approved For China Arm Of Global Phase III Cancer Trial 12/22/2015
Pfizer (PFE) Reports Top Line Results From A Phase 3 Study Evaluating Desvenlafaxine Succinate Sustained-Release Formulation In Pediatric Patients With Major Depressive Disorder 12/22/2015
Tenax Therapeutics (TENX) Highlights Completion Of Enrollment For LeoPARDS Trial By Imperial College London 12/22/2015
BeyondSpring Pharmaceuticals Granted CTA By CFDA To Initiate China Arm Of Global Phase III Trial Of Lead Asset Plinabulin 12/22/2015
Merck & Co. (MRK)’s KEYTRUDA (pembrolizumab) Significantly Improves Survival Compared To Chemotherapy In Previously-Treated Patients With Non-Small Cell Lung Cancer Whose Tumors Express Any Level Of PD-L1 12/21/2015
Baxalta (BXLT)'s ADYNOVATE Meets Endpoints in Late-Stage Study 12/21/2015
SELLAS Life Sciences Expands Leadership Team, Appoints Andres A. Gutierrez, M.D., Ph.D., As Chief Medical Officer 12/21/2015
Janssen Announces Collaboration With Bavarian Nordic (BAVA.CO) To Develop Vaccine For Chronic Human Papillomavirus (HPV) Infections 12/21/2015
Kitov (KTOV) Reports Additional Data From Its Phase III Trial On The Beneficial Blood Pressure Effects Of KIT-302 12/18/2015
Hutchison China MediTech (Chi-Med) Release: Initiation Of Sulfatinib Phase III Registration Study In Neuroendocrine Tumor Patients 12/18/2015
Boehringer Ingelheim Presents Strong Lung Cancer Portfolio And Long-Awaited Head-To-Head Data Of afatinib Compared To gefitinib At ESMO Asia 2015 Congress 12/18/2015
Genentech (RHHBY) Touts Hematology Data for Gazyva and Venetoclax in CLL 12/17/2015
Christmas Comes Early to SAGE Therapeutics (SAGE) Investors as Company Accelerates Promising Pipeline Timeline 12/17/2015
Celyad Announces The Publication Of Its CHART-1 Trial Design Methods Paper In The European Journal Of Heart Failure 12/16/2015
Inotek Pharmaceuticals Corporation (ITEK) To Webcast First Research And Development Day 12/16/2015
NeuroRx Provides Clinical Development Update For Cyclurad, A Novel Treatment For Acute Suicidal Crisis In Bipolar Disorder 12/16/2015
Array BioPharma (ARRY) Surges as Binimetinib Meets Goals in Late-Stage Study 12/16/2015
PHARNEXT Initiates PLEO-CMT, An International Pivotal Phase 3 Trial, In Charcot-Marie-Tooth Disease Type 1A 12/15/2015
Braeburn Pharma And Camurus Announces Start Of Phase 3 Trial Of Long-Acting Buprenorphine Treatments For Opioid Dependence 12/15/2015
NewLink Genetics (NLNK) Completes Enrollment Of Phase III PILLAR Trial Evaluating Algenpantucel-L For Patients With Locally Advanced Pancreatic Cancer 12/15/2015
Novavax (NVAX) Completes Enrollment Of Pivotal Phase III Trial Of The RSV F Vaccine In Older Adults 12/15/2015
NovoCure To Hold Webcast To Discuss JAMA Publication Of EF-14 Phase III Clinical Trial Data 12/15/2015
NovoCure Release: JAMA Publishes Pivotal Phase III Data For Optune Plus Temozolomide To Treat Newly Diagnosed Glioblastoma 12/15/2015
NovoCure To Hold Webcast To Discuss JAMA Publication Of EF-14 Phase 3 Clinical Trial Data 12/15/2015



//-->